Novartis OTC Plant Troubled By Quality Failures A Year After Shutdown
This article was originally published in The Tan Sheet
Executive Summary
FDA recorded nine observations – many of them repeats from 2011 and 2012 – on a form 483 during its early 2013 visit to Novartis Consumer Health’s facility in Lincoln, Nebraska. The observations cited inadequate consumer complaint handling and container closure stability testing.
You may also be interested in...
GSK Sees Excedrin Sales Growth As Consumers Visualize Headache Pain
Excedrin Extra Strength US sales for the 12 months ending Aug. 12 were up 4.07% to $77.2m, but those figures don't include the 12,000 free packages of Excedrin gel tablets consumers ordered during GSK's the Limited Edition promotion. The firm offered Excedrin in packages marked with causes consumers commonly link with headaches: commuting, bad dating and "adulting."
GSK Sees Excedrin Sales Growth As Consumers Visualize Headache Pain
Excedrin Extra Strength US sales for the 12 months ending Aug. 12 were up 4.07% to $77.2m, but those figures don't include the 12,000 free packages of Excedrin gel tablets consumers ordered during GSK's the Limited Edition promotion. The firm offered Excedrin in packages marked with causes consumers commonly link with headaches: commuting, bad dating and "adulting."
Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space
Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.